Abstract：
UNASSIGNED: In January 2017, a new funding model for diagnostic genetic testing in cancer was introduced in Poland.
UNASSIGNED: The aim of this study was to assess the impact of changing the funding model for genetic diagnosis in oncology on improving access to personalized medicine in Poland between 2017 and 2019.
UNASSIGNED: The analysis included data on settlements with the National Health Fund for genetic tests in cancer under a contract of the hospital treatment type and under the contract in the type of separately contracted services between 2017 and 2019.
UNASSIGNED: The 150,647 diagnostic genetic tests were reported, which were billed to 111,872 patients. The average number of tests per patient was 1.35. One test was billed to 83.5% of patients, 11.2% of patients had two tests billed, and 5.3% had at least three tests billed. The number of services provided under the hospital treatment contract in 2018 doubled compared to the previous year. For separately contracted services, more than threefold increase in genetic testing performed in 2019 compared to 2018 was observed.
UNASSIGNED: our data show that the novel funding model for genetic services introduced in Poland has positive impact on the availability of genetic testing for patients.
UNASSIGNED: The aim of this study was to assess the impact of changing the funding model for genetic diagnosis in oncology on improving access to personalized medicine in Poland between 2017 and 2019.
UNASSIGNED: The analysis included data on settlements with the National Health Fund for genetic tests in cancer under a contract of the hospital treatment type and under the contract in the type of separately contracted services between 2017 and 2019.
UNASSIGNED: The 150,647 diagnostic genetic tests were reported, which were billed to 111,872 patients. The average number of tests per patient was 1.35. One test was billed to 83.5% of patients, 11.2% of patients had two tests billed, and 5.3% had at least three tests billed. The number of services provided under the hospital treatment contract in 2018 doubled compared to the previous year. For separately contracted services, more than threefold increase in genetic testing performed in 2019 compared to 2018 was observed.
UNASSIGNED: our data show that the novel funding model for genetic services introduced in Poland has positive impact on the availability of genetic testing for patients.
摘要：
UNASSIGNED：2017年1月，波兰引入了一种用于癌症诊断基因检测的新资助模式。
UNASSIGNED：这项研究的目的是评估2017年至2019年期间改变肿瘤学基因诊断资助模式对改善波兰获得个性化医疗的影响。
UNASSIGNED：分析包括2017年至2019年期间，根据医院治疗类型的合同和单独签约服务类型的合同，与国家卫生基金进行癌症基因检测的结算数据。
未经评估：报告了150,647项诊断性基因测试，这是111,872名患者的账单。每位患者的平均测试次数为1.35次。一项测试向83.5%的患者收费，11.2%的患者进行了两项检查，5.3%的人至少有三项测试。2018年根据医院治疗合同提供的服务数量与上一年相比翻了一番。对于单独签约的服务，与2018年相比，2019年进行的基因检测增加了三倍以上。
UNASSIGNED：我们的数据表明，波兰引入的新的遗传服务资助模式对患者遗传检测的可用性产生了积极影响。
UNASSIGNED：这项研究的目的是评估2017年至2019年期间改变肿瘤学基因诊断资助模式对改善波兰获得个性化医疗的影响。
UNASSIGNED：分析包括2017年至2019年期间，根据医院治疗类型的合同和单独签约服务类型的合同，与国家卫生基金进行癌症基因检测的结算数据。
未经评估：报告了150,647项诊断性基因测试，这是111,872名患者的账单。每位患者的平均测试次数为1.35次。一项测试向83.5%的患者收费，11.2%的患者进行了两项检查，5.3%的人至少有三项测试。2018年根据医院治疗合同提供的服务数量与上一年相比翻了一番。对于单独签约的服务，与2018年相比，2019年进行的基因检测增加了三倍以上。
UNASSIGNED：我们的数据表明，波兰引入的新的遗传服务资助模式对患者遗传检测的可用性产生了积极影响。
